Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Kaltura Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Kaltura Inc trades at $1.38 (market cap $212.05M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 13.5× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Kaltura Inc for 21 Days on average.
| DYN | KLTR | |
|---|---|---|
Market Cap | $2.86B | $212.05M |
Volume | 3,341,579 | 264,699 |
Sector | Health | Technology |
52-Week High | $26.78 | $1.89 |
52-Week Low | $14.60 | $1.08 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $2.18B | $224.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KLTR trades at $1.37, down 2.14% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported revenue of $180.85M in 2025, with a net loss of $12.07M, though losses have narrowed significantly from prior years. Recent news highlights include Gartner naming Kaltura a leader in AI for video platform services and a strategic partnership with Verimatrix for security.
The outlook remains speculative; while AI-driven growth and improving margins present upside potential, persistent losses, high valuation ratios, and negative cash flow pose substantial risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, but the stock's high volatility and weak profitability metrics warrant careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
